(NRFU Grant 2022.01/0087 “Development of components for antimicrobial drugs to enhance their efficacy and prevent microbial resistance,” 2023–2024)

A study of the antibacterial properties of the natural metabolite 3, 3’-diindolylmethane (DIM) and its synthetic analogs on standard and clinical strains of bacteria from the ESKAPE group  showed that  DIM is capable of breaking down the resistance of microorganisms in this group to certain antibacterial active pharmaceutical ingredients (APIs).  This result served as the basis  for  the successful development, in collaboration with specialists from our institution’s Department of Drug Technology and Analysis, researchers  from V.N. Karazin Kharkiv National University, and the Institute of Dermatology and Venereology  of the National Academy of Medical Sciences of Ukraine, of experimental ointment formulations for the treatment of purulent wounds. 

Stages of developing a new drug based on diindolylmethane (DIM)

(Biological Safety Project, 2023–2025)

In collaboration with other departments, a prototype of the Lepto-RT-PCR test system has been developed. This system is designed to detect DNA of pathogenic Leptospira spp. strains using real-time polymerase chain reaction (with the intercalating dye Krystal Green). The ability of the Lepto-RT-PCR prototype to detect up to 100 genomic equivalents in the reaction has been demonstrated.

Lepto-RT-PCR Test System for the Detection of DNA from Pathogenic Strains of Leptospira spp.